Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVENUE THERAPEUTICS, INC.ATXI · Entity 8537 | Director | August 07, 2018 | August 08, 2018 |
| Fortress Biotech, Inc.FBIO · Entity 6822 | Director · Executive Vice Chairman | March 18, 2026 | March 20, 2026 |
| MUSTANG BIO, INC.MBIO · Entity 8350 | Director | July 05, 2023 | July 07, 2023 |
| NATIONAL HOLDINGS CORPNHLD · Entity 142239 | Director · 10% owner | September 12, 2016 | September 22, 2016 |
| TG THERAPEUTICS, INC.TGTX · Entity 3608 | Director · CEO | January 08, 2026 | January 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVENUE THERAPEUTICS, INC.
Report date August 07, 2018 · Filed August 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,663 |
Reported balance
After 2018-08-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-08-07 · Gift · Acquired 14,663 · Balance 24,663 F1: The 14,663 shares of restricted common stock will vest on August 7, 2021. F2: Includes 24,663 shares of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The 14,663 shares of restricted common stock will vest on August 7, 2021.
F2: Includes 24,663 shares of restricted stock.
Fortress Biotech, Inc.
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common stock, par value $0.001SEC Table I · non-derivative | Direct | 2,276,562 |
Reported balance
After 2026-03-18 transaction · row 1
1 source rowRow 1 · 2026-03-18 · Grant · Acquired 475,424 · Balance 2,276,562 F1: The Reporting Person was granted 475,424 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on March 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 475,424 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on March 18, 2026.
MUSTANG BIO, INC.
Report date July 05, 2023 · Filed July 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.0001SEC Table I · non-derivative | IndirectSee Footnote | 49,637 |
Reported balance
After 2023-07-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-07-05 · Grant · Acquired 7,246 · Balance 49,637 F1: The Reporting Person was granted 7,246 restricted shares pursuant to the Issuer's 2016 Incentive Plan on July 5, 2023. The shares will vest on July 5, 2026, subject to the Reporting Person's continued service on the Issuer's board on such date. F2: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F3: Includes restricted share units, which vest over various time periods. F4: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 7,246 restricted shares pursuant to the Issuer's 2016 Incentive Plan on July 5, 2023. The shares will vest on July 5, 2026, subject to the Reporting Person's continued service on the Issuer's board on such date.
F2: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.
F3: Includes restricted share units, which vest over various time periods.
F4: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member.
NATIONAL HOLDINGS CORP
Report date September 12, 2016 · Filed September 22, 2016
Jointly reported with FBIO Acquisition, Inc., Fortress Biotech, Inc., Opus Point Partners, LLC, Opus Point Healthcare Innovations (Offshore) Fund Ltd., ROSENWALD LINDSAY A MD
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,037,482 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,037,482 F1: These securities are owned directly by FBIO Acquisition, Inc. ("FBIO Acquisition"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) FBIO Acquisition, (ii) Fortress Biotech, Inc. ("FBIO"), (iii) Opus Point Partners, LLC ("Opus Point Partners"), (iv) Opus Point Healthcare Innovations (Offshore) Fund Ltd. ("Opus Point Healthcare"), (v) Lindsay A. Rosenwald, M.D. and (vi) Michael S. Weiss (collectively, the "FBIO Group"), and indirectly by FBIO, by its ownership of FBIO Acquisition. Each of the members of the FBIO Group, other than FBIO Acquisition and FBIO, disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 371,584 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 371,584 F2: These securities are owned directly by Opus Point Partners, and indirectly by Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition, FBIO and Opus Point Healthcare disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 89,530 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 89,530 F3: These securities are owned directly by Opus Point Healthcare, and indirectly by Opus Point Partners and Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition and FBIO disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 44,884 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 44,884 F4: These securities are owned directly by Mr. Weiss. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 16,294 |
Reported balance
Holding disclosure · report date 2016-09-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 16,294 F5: These securities are owned directly by Dr. Rosenwald. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are owned directly by FBIO Acquisition, Inc. ("FBIO Acquisition"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) FBIO Acquisition, (ii) Fortress Biotech, Inc. ("FBIO"), (iii) Opus Point Partners, LLC ("Opus Point Partners"), (iv) Opus Point Healthcare Innovations (Offshore) Fund Ltd. ("Opus Point Healthcare"), (v) Lindsay A. Rosenwald, M.D. and (vi) Michael S. Weiss (collectively, the "FBIO Group"), and indirectly by FBIO, by its ownership of FBIO Acquisition. Each of the members of the FBIO Group, other than FBIO Acquisition and FBIO, disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F2: These securities are owned directly by Opus Point Partners, and indirectly by Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition, FBIO and Opus Point Healthcare disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F3: These securities are owned directly by Opus Point Healthcare, and indirectly by Opus Point Partners and Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition and FBIO disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F4: These securities are owned directly by Mr. Weiss. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F5: These securities are owned directly by Dr. Rosenwald. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
TG THERAPEUTICS, INC.
Report date January 08, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,778,086 |
Reported balance
After 2026-01-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-08 · Grant · Acquired 622,000 · Balance 9,778,086 F1: Reflects a grant of restricted shares, all of which will vest on the first anniversary of the date on which the first of any of the following occur: (i) the Company's total shareholder return (TSR) exceeds the TSR of the Nasdaq Biotechnology Index (NBI) over a 3-year period; (ii) the Company's TSR exceeds the TSR of the NBI over a 5-year period; (iii) the Company's TSR exceeds the TSR of the NBI over a 7-year period; or (iv) the Company's TSR exceeds the TSR of the NBI over a 9-year period. F2: Includes shares of restricted Common Stock, which vest over various time periods. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted shares, all of which will vest on the first anniversary of the date on which the first of any of the following occur: (i) the Company's total shareholder return (TSR) exceeds the TSR of the Nasdaq Biotechnology Index (NBI) over a 3-year period; (ii) the Company's TSR exceeds the TSR of the NBI over a 5-year period; (iii) the Company's TSR exceeds the TSR of the NBI over a 7-year period; or (iv) the Company's TSR exceeds the TSR of the NBI over a 9-year period.
F2: Includes shares of restricted Common Stock, which vest over various time periods.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Checkpoint Therapeutics, Inc.
Report date May 28, 2025 · Filed May 30, 2025
Section 16 reporting ended · disclosed 2025-05-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | IndirectSee Note 2 | 137,007 |
Reported balance
After 2025-05-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-05-28 · Grant · Acquired 12,195 · Balance 137,007 F1: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Weiss's continued service on the board. F2: The shares were held by Hawkins BioVentures, LLC, of which Mr. Weiss is the sole member. |
| COMMON STOCKSEC Table I · non-derivative | IndirectSee Note 2 | 0 |
Reported balance
After 2025-05-30 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-05-30 · Other · Disposed 187,007 · Balance 0 F3: Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency. F2: The shares were held by Hawkins BioVentures, LLC, of which Mr. Weiss is the sole member. |
| COMMON STOCKSEC Table I · non-derivative | Direct | 187,007 |
Reported balance
After 2025-05-29 transaction · row 2
1 source rowRow 2 · 2025-05-29 · Grant · Acquired 50,000 · Balance 187,007 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Weiss's continued service on the board.
F2: The shares were held by Hawkins BioVentures, LLC, of which Mr. Weiss is the sole member.
F3: Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2026 Filed Mar 20, 2026 16:05 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | Grantcommon stock, par value $0.001 | 475,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001038977-26-000002 · form4-03202026_040301.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · Executive Vice Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,276,562 F1 · shares: The Reporting Person was granted 475,424 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on March 18, 2026. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 22:16 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 622,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-001016 · rdgdoc.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,778,086 F1 · shares: Reflects a grant of restricted shares, all of which will vest on the first anniversary of the date on which the first of any of the following occur: (i) the Company's total shareholder return (TSR) exceeds the TSR of the Nasdaq Biotechnology Index (NBI) over a 3-year period; (ii) the Company's TSR exceeds the TSR of the NBI over a 5-year period; (iii) the Company's TSR exceeds the TSR of the NBI over a 7-year period; or (iv) the Company's TSR exceeds the TSR of the NBI over a 9-year period. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 22:01 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCommon Stock | 803,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-033888 · rdgdoc.xml · nonDerivative · entry 2 WEISS MICHAEL S · CIK 0001038977 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,156,086 F3 · shares: Represents the transfer of shares to The Weiss Family and Descendants Trust. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 22:01 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCommon Stock | 3,865,126 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-033888 · rdgdoc.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,959,803 F1 · shares: Represents distribution of shares upon termination of the Michael Sean Weiss 2022 Grantor Retained Annuity Trust to irrevocable trusts for the benefit of Mr. Weiss' children. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| May 30, 2025 Filed May 30, 2025 11:21 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | OtherCOMMON STOCK | 187,007 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-054698 · tm2516581-8_4seq1.xml · nonDerivative · entry 3 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Note 2 Disclosed balance after: 0 F3 · price: Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency. F2 · ownership.nature: The shares were held by Hawkins BioVentures, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| May 29, 2025 Filed May 30, 2025 11:21 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 50,000 | $1.29 | $64,500.00 |
DisclosureSEC source: 0001104659-25-054698 · tm2516581-8_4seq1.xml · nonDerivative · entry 2 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,007 Read SEC document |
| May 28, 2025 Filed May 30, 2025 11:21 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 12,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-054698 · tm2516581-8_4seq1.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Note 2 Disclosed balance after: 137,007 F1 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Weiss's continued service on the board. F2 · ownership.nature: The shares were held by Hawkins BioVentures, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| January 29, 2025 Filed Jan 30, 2025 22:17 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002292 · rdgdoc.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,824,929 F1 · shares: Reflects a grant of restricted shares, all of which will vest on the first anniversary of the date on which the first of any of the following occur: (i) the Company's total shareholder return (TSR) exceeds the TSR of the Nasdaq Biotechnology Index (NBI) over a 3-year period; (ii) the Company's TSR exceeds the TSR of the NBI over a 5-year period; (iii) the Company's TSR exceeds the TSR of the NBI over a 7-year period; or (iv) the Company's TSR exceeds the TSR of the NBI over a 9-year period. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 16:15 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | Grantcommon stock, par value $0.001 | 454,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000402 · form4-01032025_040105.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · Executive Vice Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,801,138 F1 · shares: The Reporting Person was granted 454,153 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on January 1, 2025. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 21:33 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 12,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-129528 · tm2431396-8_4seq1.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Note 3 Disclosed balance after: 124,812 F1 · shares: Represents previously-granted performance-based award that became vested upon achievement of a corporate milestone on December 13, 2024. F2 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Weiss's continued service on the board. F3 · ownership.nature: The shares are held by Hawkins BioVentures, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| May 14, 2024 Filed May 16, 2024 19:35 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-062667 · tm2414703-6_4seq1.xml · nonDerivative · entry 2 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Note 3 Disclosed balance after: 112,174 F4 · shares: The 50,000 shares of restricted Common Stock will vest according to the following schedule, subject to Mr. Weiss's continued service on the board on each date: one third on May 14, 2027, one third on May 14, 2028, and one third on May 14, 2029. F2 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Weiss's continued service on the board. F3 · ownership.nature: The shares are held by Hawkins BioVentures, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| May 14, 2024 Filed May 16, 2024 19:35 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 32,051 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-062667 · tm2414703-6_4seq1.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Note 3 Disclosed balance after: 62,174 F1 · shares: The 32,051 shares of restricted Common Stock will vest on May 14, 2027, subject to Mr. Weiss's continued service on the board on such date. F2 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Weiss's continued service on the board. F3 · ownership.nature: The shares are held by Hawkins BioVentures, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| January 06, 2024 Filed Jan 8, 2024 23:32 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 1,001,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-000899 · rdgdoc.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,074,929 F1 · shares: Reflects a grant of restricted shares, which will vest and become non-forfeitable based on the Company's total shareholder return relative to the Nasdaq Biotechnology Index over a one-year to five-year period, provided that the Reporting Person remains an employee, director and/or consultant of the Company through each vesting date. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 16:48 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 216,465 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-000900 · tm241755-12_4seq1.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,346,985 F1 · shares: The Reporting Person was granted 216,465 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on January 1, 2024. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 17:46 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseWarrants to purchase Common Stock · Derivative | 147,058 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001104659-23-119186 · tm2330934-1_4seq1.xml · derivative · entry 2 WEISS MICHAEL S · CIK 0001038977 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,058 Underlying: Common Stock · 147,058 shares Expires 2028-11-14 F2 · price: The shares of common stock and warrants to purchase common stock reflect on this Form 4 were purchased as units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at a price per unit of $1.70. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 17:46 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 147,058 | $1.70 | $249,998.60 |
DisclosureSEC source: 0001104659-23-119186 · tm2330934-1_4seq1.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,130,520 F1 · shares: Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. F2 · price: The shares of common stock and warrants to purchase common stock reflect on this Form 4 were purchased as units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at a price per unit of $1.70. F1 · balance_after: Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. Read SEC document |
| August 11, 2023 Filed Aug 14, 2023 13:54 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | PurchaseCOMMON STOCK | 100,000 | $10.13 | $1,013,000.00 |
DisclosureSEC source: 0001104659-23-091054 · tm2323684-1_4seq1.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,073,021 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $10.11 to $10.17. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 16:06 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 7,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-079112 · tm2320790-3_4seq1.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 49,637 F1 · shares: The Reporting Person was granted 7,246 restricted shares pursuant to the Issuer's 2016 Incentive Plan on July 5, 2023. The shares will vest on July 5, 2026, subject to the Reporting Person's continued service on the Issuer's board on such date. F2 · shares: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F2 · balance_after: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F3 · balance_after: Includes restricted share units, which vest over various time periods. F4 · ownership.nature: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:01 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 17,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-071761 · tm2318836-6_4seq1.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Note 3 Disclosed balance after: 30,123 F1 · shares: The 17,483 shares of restricted Common Stock will vest on June 13, 2026, subject to Mr. Weiss's continued service on the board on such date. F2 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Weiss's continued service on the board. F3 · ownership.nature: The shares are held by Hawkins BioVentures, LLC, Mr. Weiss is the sole member. Read SEC document |
| March 12, 2023 Filed Mar 14, 2023 21:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 985,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-032337 · tm239588-1_4seq1.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,973,021 F1 · shares: Reflects a grant of restricted shares, which will vest and become non-forfeitable based on the Company's total shareholder return relative to the Nasdaq Biotechnology Index over a one-year to five-year period, provided that the Reporting Person remains an employee, director and/or consultant of the Company through each vesting date. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 16:12 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 1,197,604 | $0.84 | $999,999.34 |
DisclosureSEC source: 0001104659-23-021628 · tm236803-6_4seq1.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,752,034 Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 21:27 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 1,219,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001101 · tm231728-7_4seq1.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,554,430 F1 · shares: The Reporting Person was granted 1,219,294 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on January 1, 2023. Read SEC document |
| July 29, 2022 Filed Apr 3, 2023 16:48 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 71,664 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-040923 · tm2311237d1_4seq1.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Note 3 Disclosed balance after: 135,861 F1 · shares: The Reporting Person was granted 71,664 restricted shares pursuant to the Issuer's 2016 Incentive Plan on July 29, 2022. The shares will vest on June 17, 2025, subject to the Reporting Person's continued service on the Issuer's board on such date. F2 · balance_after: Includes restricted share units, which vest over various time periods. F3 · ownership.nature: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| July 20, 2022 Filed Jul 22, 2022 20:34 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantStock Option (right to buy) · Derivative | 1,900,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082027 · tm2221660-7_4seq1.xml · derivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900,000 Underlying: Common Stock, par value $0.001 · 1,900,000 shares Expires 2027-07-20 F1 · derivative.exercise_date: Reflects a grant of options relating to 2021 service and performance, of which 1/3 will vest on 7/20/2024, 1/3 will vest on 7/20/2025, and 1/3 will vest on 7/20/2026. Read SEC document |
| June 16, 2022 Filed Jun 24, 2022 21:53 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 47,619 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-074464 · tm2219319-1_4seq1.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 126,401 F1 · shares: The 47,619 shares of restricted Common Stock will vest on June 16, 2025, subject to Mr. Weiss's continued service on the board on such date. F2 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Weiss's continued service on the board. F3 · ownership.nature: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 23:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCOMMON STOCK | 30,671 | $18.31 | $561,586.01 |
DisclosureSEC source: 0001104659-22-002355 · tm222217d2_4.xml · nonDerivative · entry 6 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,988,021 F4 · shares: In connection with the vesting of 225,000 shares held by Mr. Weiss' dependents on January 1, 2022, these shares were sold by the Company's restricted stock administrator in order to satisfy tax withholding obligations. Mr. Weiss nor his dependents had any discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F5 · balance_after: Includes 2,437,005 shares received as a liquidating distribution from Opus Point Partners, LLC ("Opus"), of which Mr. Weiss was a principal. In prior reports, Mr, Weiss reported beneficial ownership of all 4,874,010 shares held by Opus, even though he only owned 50% of Opus. On December 29, 2021, as part of the dissolution of Opus the shares of TGTX held by Opus were distributed to the underlying Opus owners. As a result of such distribution, the 2,437,005 shares held indirectly by the reporting person are no longer held by the reporting person. Read SEC document |
| January 04, 2022 Filed Jan 7, 2022 23:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCOMMON STOCK | 37,549 | $19.20 | $720,940.80 |
DisclosureSEC source: 0001104659-22-002355 · tm222217d2_4.xml · nonDerivative · entry 5 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,455,697 F4 · shares: In connection with the vesting of 225,000 shares held by Mr. Weiss' dependents on January 1, 2022, these shares were sold by the Company's restricted stock administrator in order to satisfy tax withholding obligations. Mr. Weiss nor his dependents had any discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. Read SEC document |
| January 01, 2022 Filed Apr 29, 2022 16:24 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 1,102,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-053619 · tm2213913-8_4seq1.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,335,136 F1 · shares: The Reporting Person was granted 1,102,986 restricted shares pursuant to the Issuer's Long Term Incentive Plan on January 1, 2022. Read SEC document |
| December 29, 2021 Filed Jan 7, 2022 23:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 56,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-002355 · tm222217d2_4.xml · nonDerivative · entry 4 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,493,246 F3 · shares: Reflects a grant of restricted shares of common stock of TG Therapeutics in lieu of cash compensation owed to Mr. Weiss for the 2021 fiscal year, which will fully vest on January 1, 2024. Read SEC document |
| December 16, 2021 Filed Jan 7, 2022 23:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCOMMON STOCK | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-002355 · tm222217d2_4.xml · nonDerivative · entry 3 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,436,852 F1 · shares: Reflects the transfer of shares of TG Therapeutics stock as a bona fide gift to various 501(c)(3) charitable organizations. Read SEC document |
| December 16, 2021 Filed Jan 7, 2022 23:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCOMMON STOCK | 700,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-002355 · tm222217d2_4.xml · nonDerivative · entry 2 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,445,852 F2 · shares: Reflects the transfer of shares of TG Therapeutics stock to various trusts for the benefit of Mr. Weiss' dependents. Read SEC document |
| December 15, 2021 Filed Jan 7, 2022 23:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCOMMON STOCK | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-002355 · tm222217d2_4.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,145,852 F1 · shares: Reflects the transfer of shares of TG Therapeutics stock as a bona fide gift to various 501(c)(3) charitable organizations. Read SEC document |
| June 28, 2021 Filed Jul 8, 2021 16:32 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK | 13,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-090246 · tm2121675-5_4seq1.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 64,197 F1 · shares: 13,774 restricted shares were granted pursuant to the Issuer's 2016 Incentive Plan on June 28, 2021. The shares will vest on June 17, 2024, subject to the Reporting Person's continued service on the Issuer's board on such date. F2 · balance_after: Includes restricted share units, which vest over various time periods. F3 · ownership.nature: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:26 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 1,080,770 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-084261 · tm2120405-6_4seq1.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,148,852 F1 · shares: Reflects the final annual grant of restricted stock pursuant to the Strategic Advisory Agreement with Caribe BioAdvisors, LLC, pursuant to which Mr. Weiss provided the services of Chairman of the Board and Executive Chairman. The restricted shares will vest on the date that the Company's Market Capitalization is $500 million greater than the Market Capitalization on the date of grant as measured within a five-year timeframe, but in no event before December 1, 2022. F2 · balance_after: Included in Mr. Weiss' beneficial ownership are 4,909,355 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a principal and beneficially owns a 50% interest. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:01 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 16,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-080364 · tm2119513-5_4.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 78,782 F1 · shares: The 16,502 shares of restricted Common Stock will vest on June 10, 2024, subject to Mr. Weiss's continued service on the board on such date. F2 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Weiss's continued service on the board. F3 · ownership.nature: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| January 01, 2021 Filed Apr 9, 2021 17:26 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 1,030,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-048834 · tm219139d8_4.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,232,150 F1 · shares: The Reporting Person was granted 1,030,339 restricted shares pursuant to the Issuer's Long Term Incentive Plan on January 1, 2021. Read SEC document |
| December 28, 2020 Filed Dec 31, 2020 21:30 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCOMMON STOCK | 655 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-140992 · tm2039708-1_form5.xml · nonDerivative · entry 8 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 13,068,082 F2 · security: Reflect the transfer of shares as a bona fide gift to various 501(c)(3) charitable organizations. F3 · balance_after: Included in Mr. Weiss' beneficial ownership are 4,909,355 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest. Read SEC document |
| December 28, 2020 Filed Dec 31, 2020 21:30 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCOMMON STOCK | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-140992 · tm2039708-1_form5.xml · nonDerivative · entry 7 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,068,737 F2 · security: Reflect the transfer of shares as a bona fide gift to various 501(c)(3) charitable organizations. Read SEC document |
| December 22, 2020 Filed Dec 31, 2020 21:30 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCOMMON STOCK | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-140992 · tm2039708-1_form5.xml · nonDerivative · entry 6 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,069,737 F2 · security: Reflect the transfer of shares as a bona fide gift to various 501(c)(3) charitable organizations. Read SEC document |
| December 15, 2020 Filed Dec 31, 2020 21:30 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCOMMON STOCK | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-140992 · tm2039708-1_form5.xml · nonDerivative · entry 5 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,069,937 F2 · security: Reflect the transfer of shares as a bona fide gift to various 501(c)(3) charitable organizations. Read SEC document |
| December 15, 2020 Filed Dec 31, 2020 21:30 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCOMMON STOCK | 1,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-140992 · tm2039708-1_form5.xml · nonDerivative · entry 4 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,070,137 F2 · security: Reflect the transfer of shares as a bona fide gift to various 501(c)(3) charitable organizations. Read SEC document |
| December 15, 2020 Filed Dec 31, 2020 21:30 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCOMMON STOCK | 834,877 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-140992 · tm2039708-1_form5.xml · nonDerivative · entry 3 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,071,837 F1 · security: Reflects the transfer of shares of TG Therapeutics stock to the Weiss Family and Descendants Trust. Read SEC document |
| September 25, 2020 Filed Dec 31, 2020 21:30 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCOMMON STOCK | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-140992 · tm2039708-1_form5.xml · nonDerivative · entry 2 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,906,714 F2 · security: Reflect the transfer of shares as a bona fide gift to various 501(c)(3) charitable organizations. Read SEC document |
| September 10, 2020 Filed Dec 31, 2020 21:30 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GiftCOMMON STOCK | 525,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-140992 · tm2039708-1_form5.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,909,214 F1 · security: Reflects the transfer of shares of TG Therapeutics stock to the Weiss Family and Descendants Trust. Read SEC document |
| July 14, 2020 Filed Aug 19, 2020 16:33 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCommon Stock | 16,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-096926 · tm2028955d4_4.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,423 F1 · balance_after: Includes 50,423 restricted stock units which vest over time. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 23:51 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 1,556,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-076547 · tm2022959-7_4.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 14,434,214 F1 · shares: Reflects an annual grant of restricted stock pursuant to the Strategic Advisory Agreement with Caribe BioAdvisors, LLC, pursuant to which Mr. Weiss provides the services of Chairman of the Board and Executive Chairman. The restricted shares will vest on the date that the Company's Market Capitalization is $100 million greater than the Market Capitalization on the date of grant, but in no event before December 31, 2020. F2 · balance_after: Included in Mr. Weiss' beneficial ownership are 4,910,010 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest. F3 · ownership.nature: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 16:33 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 24,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-071414 · tm2022118d5_4.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 62,280 F1 · shares: The 24,390 shares of restricted Common Stock will vest on June 5, 2023, subject to Mr. Weiss's continued service on the board on such date. F2 · balance_after: Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Weiss's continued service on the board. F3 · ownership.nature: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. Read SEC document |
| January 01, 2020 Filed Mar 13, 2020 16:08 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 801,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-033118 · tm2011481-8_form4.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · EXECUTIVE VICE CHAIRMAN · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,201,811 F1 · shares: The Reporting Person was granted 801,536 restricted shares pursuant to the Issuer's Long Term Incentive Plan on January 1, 2020. Read SEC document |
| August 28, 2019 Filed Jan 17, 2020 17:43 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCommon Stock | 13,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-005209 · tm203350d2_form4.xml · nonDerivative · entry 2 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,812 F2 · balance_after: Includes 33,812 restricted stock units which vest over time. Read SEC document |
| June 26, 2019 Filed Jun 27, 2019 11:33 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | PurchaseCOMMON STOCK | 50,000 | $7.04 | $351,750.00 |
DisclosureSEC source: 0001654954-19-007706 · section16.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 12,878,185 F1 · shares: Mr. Weiss purchased 50,000 shares in the open market at a price of $7.035 per share. F2 · balance_after: Included in Mr. Weiss' beneficial ownership are 4,910,010 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest. F3 · ownership.nature: The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.